Olopatadine versus levocetirizine in chronic urticaria: an observer-blind, randomized, controlled trial of effectiveness and safety

References

• Greaves MW, Sabroe RA. Allergy and the skin I: Urticaria. Br Med J. 1998;316:1147–1150.
   Google Scholar
• Sheldon JM, Mathews KP, Lovell RG. The vexing urticaria problem: present concepts of etiology and management. J Allergy. 1954;25:525–560.
   PubMedGoogle Scholar
• Kozel MM, Mekkes JR, Bossuyt PM, Bos JD. The effectiveness of a history-based diagnostic approach in chronic urticaria and angioedema. Arch Dermatol. 1998;134:1575–1580.
   PubMedGoogle Scholar
• Lindelof B, Sigurgeirsson B, Wahlgren CF, Eklund G. Chronic urticaria and cancer: an epidemiological study of 1155 patients. Br J Dermatol. 1990;123:453–456.
   PubMed Web of Science ®Google Scholar
• Warin RP. Food and factors in urticaria. J Hum Nutr. 1976;30:179–186.
   Google Scholar
• Sabroe RA, Greaves MW. The pathogenesis of chronic idiopathic urticaria. Arch Dermatol. 1997;133:1003–1008.
   PubMed Web of Science ®Google Scholar
• Hellgren L, Hersle K. Acute and chronic urticaria. A statistical investigation on clinical and laboratory data in 1204 patients and matched healthy controls. Acta Allergol. 1964;19:406–420.
   Google Scholar
• Sehgal VN, Rege VL. An interrogative study of 158 urticaria patients. Ann Allergy. 1973;31:279–283.
   PubMedGoogle Scholar
• Kaplan AP, Horakova Z, Katz SI. Assessment of tissue fluid histamine levels in patients with urticaria. J Allergy Clin Immunol. 1978;61:350–354.
   PubMed Web of Science ®Google Scholar
• Phanuphak P, Schocket AL, Arroyave CM, Kohler PF. Skin histamine in chronic urticaria. J Allergy Clin Immunol. 1980;65:371–375.
   PubMed Web of Science ®Google Scholar
• Ohmori K, Hayashi K, Kaise T, Ohshima E, Kobayashi S, Yamazaki T, et al. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride: A new antiallergic drug. Jpn J Pharmacol. 2002;88:379–397.
   PubMedGoogle Scholar
• Giustizieri ML, Albanesi C, Fluhr J, Gisondi P, Norgauer J, Girolomoni G. H1 receptor mediates inflammatory responses in human keratinocytes. J Allergy Clin Immunol. 2004;114:1176–1182.
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Cirillo I, Vizzaccaro A, Tosca MA. Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: a pilot study. Clin Exp Allergy. 2004;34:958–964.
   PubMed Web of Science ®Google Scholar
• Furukawa H, Takahashi M, Nakamura K, Kaneko F. Effect of an antiallergic drug (Olopatadine hydrochloride) on TARC/CCL17 and MDC/CCL22 production by PBMCs from patients with atopic dermatitis. J Dermatol Sci. 2004;36:165–172.
   PubMedGoogle Scholar
• Okubo Y, Shigoka Y, Yamazaki M, Tsuboi R. Double dose of cetirizine hydrochloride is effective for patients with urticaria resistant: a prospective, randomized, non-blinded, comparative clinical study and assessment of quality of life. J Dermatolog Treat. 2011; Epub ahead of print.
   Google Scholar
• Staevska M, Popov TA, Kralimarkova T, Lazarova C, Kraeva S, Popova D, et al. The effectiveness of levocetirizine and desloratidine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol. 2010;125:676–682.
   PubMed Web of Science ®Google Scholar
• Philpott H, Kette F, Hissaria P, Gillis D, Smith W. Chronic urticaria: the autoimmune paradigm. Intern Med J. 2008;38:852–857.
   PubMedGoogle Scholar
• Anuradha P, Maiti R, Jyothirmai J, Mujeebuddin O, Anuradha M. Loratidine versus levocetirizine in chronic idiopathic urticaria: A comparative study of efficacy and safety. Indian J Pharmacol. 2010;42:12–16.
   PubMed Web of Science ®Google Scholar
• Godse KV. Olopatadine in chronic idiopathic urticaria. Indian J Dermatol. 2009;54:191–192.
   Google Scholar
• Erbagci Z. The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo- controlled, crossover clinical study. J Aller Clin Immunol. 2002;110:484–488.
   PubMed Web of Science ®Google Scholar
• Bajaj AK, Upadhyay A, Damisetty R, Dhar S. Autologous serum therapy in chronic urticaria: Old wine in a new bottle. Indian J Dermatol Venereol Leprol. 2008;74:109–113.
   PubMed Web of Science ®Google Scholar
• Bonifati C, Berardesca E. Clinical outcome measures of psoriasis. Reumatismo. 2007;59:64–67.
   PubMedGoogle Scholar
• Finlay AY. Quality of life indices. Indian J Dermatol Venereol Leprol. 2004;70:143–148.
   Google Scholar
• Kozel MM, Mekkes IR, Bossuyt PM, Bos JD. Natural course of physical and chronic urticaria and angieoedema in 220 patients. J Am Acad Dermatol. 2011;45:387–391.
   Google Scholar
• Potter PC, Kapp A, Maurer M, Guillet G, Jian AM, Hauptmann P, et al. Comparison of the efficacy of levocetirizine 5 mg and desloratidine 5 mg in chronic idiopathic urticaria patients. Allergy. 2009;64:596–604.
   PubMed Web of Science ®Google Scholar
• Ohmori K, Hayashi K, Kaise T, Ohshima E, Kobayashi S, Yamazaki T, et al. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn J Pharmacol. 2002;88:379–397.
   PubMedGoogle Scholar
• Takahashi H, Zhang Y, Morita E. Evaluation of the antihistamine effects of olopatadine, cetirizine and fexofenadine during a 24 h period: a double-blind, randomized, crossover, placebo-controlled comparison in skin responses induced by histamine iontophoresis. Arch Dermatol Res. 2008;300:291–295.
   Google Scholar
• Hashimoto T, Ishii N, Hamada T, Dainichi T, Karashima T, Nakama T, et al. Effects of olopatadine hydrochloride, a histamine H1 receptor antagonist, on histamine-induced skin responses. Dermatol Res Pract. 2010; Epub 2010 Sep 16.
   Google Scholar
• Dubuske LM. Levocetirizine: the latest treatment option for allergic rhinitis and chronic idiopathic urticaria. Allergy Asthma Proc. 2007;28:724–734.
   PubMedGoogle Scholar